{"id":"W2621746631","doi":"10.1002/hon.2437_3","title":"INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Clinical endpoint; Interim analysis; Ixazomib; Phases of clinical research; Adverse effect; EZH2; Surrogate endpoint; Pharmacology; Refractory (planetary science); Clinical trial; Lenalidomide; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004799916,0.001149355,0.001661461,0.0003364047,0.0004182968,0.001109225,0.000621543,0.00136815,0.007691439],"category_scores_gemma":[0.002141649,0.0004475421,0.001239293,0.0003543167,0.0003087043,0.00076659,0.0004633128,0.001742833,0.001754158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005279495,"about_ca_system_score_gemma":0.001180522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005401982,"about_ca_topic_score_gemma":0.001170351,"domain_scores_codex":[0.9990038,0.0004662818,0.00009499797,0.0001354602,0.0001503482,0.0001490878],"domain_scores_gemma":[0.9980268,0.0004370386,0.0004159967,0.0001635171,0.0002912329,0.0006653615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7084281,0.01622187,0.03116257,0.001719289,0.006213245,0.0009150788,0.000284341,0.002691143,0.03764419,0.0003334532,0.04843538,0.1459514],"study_design_scores_gemma":[0.4649191,0.3647766,0.1118436,0.000197807,0.00401303,0.001006877,0.00008802173,0.001231305,0.01000249,0.000526128,0.04131801,0.00007700724],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8608244,0.0159935,0.006749229,0.004528557,0.001731077,0.01847878,0.06944618,0.0007569697,0.02149137],"genre_scores_gemma":[0.8836017,0.005143676,0.007064644,0.006045365,0.001376922,0.01533246,0.06408276,0.0002089143,0.01714351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007691439,"threshold_uncertainty_score":0.02573043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03091780164131205,"score_gpt":0.3516476903810811,"score_spread":0.320729888739769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}